94 results
8-K
EX-99.1
EPIX
Essa Pharma Inc
29 Jan 24
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
9:15am
long-term benefits of masofaniten in patients with metastatic castration-resistant prostate cancer ("mCRPC") and to providing future updates.”
Poster … resulting from masofaniten in combination with enzalutamide, the potential long-term benefits of masofaniten, providing future updates on the Phase 1/2
8-K
EX-99.1
EPIX
Essa Pharma Inc
12 Dec 23
Results of Operations and Financial Condition
7:01am
to, statements regarding the favorable pharmaceutical properties of masofaniten, the potential clinical benefits of masofaniten in combination with other
8-K
EX-1.1
3lw0st0
6 Nov 23
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
4:57pm
424B5
148 9dqttoc5
3 Nov 23
Prospectus supplement for primary offering
9:44pm
8-K
EX-3.1
1ojirwebecmd5v6br8d
15 Sep 23
Amendments to Articles of Incorporation or Bylaws
7:56pm
8-K
EX-99.1
ef4jh
8 Aug 23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing
7:15am
8-K
EX-99.1
d9tt99u
10 May 22
ESSA Pharma Provides Corporate Update and Reports Financial Results for Clinical and Corporate Highlights
7:07am
8-K
EX-99.1
z12s01
10 Mar 22
Submission of Matters to a Vote of Security Holders
10:52am